Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEALEY ALS Platform Trial
NCT04297683Phase 3Active, not recruiting
- Start
- Jun 2020
- Primary completion
- Jul 2027
- Modality
- Nanoparticles, Cyclic Peptides, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zilucoplan, verdiperstat, CNM-Au8, pridopidine, trehalose and 3 more in amyotrophic lateral sclerosis (ALS) (8 arms). Primary endpoint: Disease Progression at 36 weeks. Started Jun 2020; status: active, not recruiting.
02
Drugs
zilucoplanverdiperstatCNM-Au8pridopidinetrehalose
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04297683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297683.